Rebecca Arend: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

51

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

Arend, Rebecca C., Londoño-Joshi, Angelina I., Gangrade, Abhishek, Katre, Ashwini A., Kurpad, Chandrika, Li, Yonghe, Samant, Rajeev S., Li, Pui-Kai, Landen, Charles N., Yang, Eddy S., Hidalgo, Bertha,

Journal:

Year:

2016

Language:

english

File:

PDF, 4.01 MB

english, 2016

52

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Sale, Matthew J., Balmanno, Kathryn, Saxena, Jayeta, Ozono, Eiko, Wojdyla, Katarzyna, McIntyre, Rebecca E., Gilley, Rebecca, Woroniuk, Anna, Howarth, Karen D., Hughes, Gareth, Dry, Jonathan R., Arends

Journal:

Nature Communications

Year:

2019

Language:

english

File:

PDF, 5.19 MB

english, 2019

53

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer

Roane, Brandon M., Arend, Rebecca C., Birrer, Michael J.

Journal:

Year:

2019

Language:

english

File:

PDF, 577 KB

english, 2019

54

A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: a Randomized, Controlled Trial

Cohen, Caroline W., Fontaine, Kevin R., Arend, Rebecca C., Gower, Barbara A.

Journal:

Nutrition and Cancer

Year:

2019

Language:

english

File:

PDF, 1.03 MB

english, 2019

55

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics

Anderson, Kenneth C, Landgren, Ola, Arend, Rebecca C, Chou, Jeffrey, Jacobs, Ira A

Journal:

Future Oncology

Year:

2019

Language:

english

File:

PDF, 1.43 MB

english, 2019

56

A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: a Randomized, Controlled Trial

Cohen, Caroline W., Fontaine, Kevin R., Arend, Rebecca C., Gower, Barbara A.

Journal:

Nutrition and Cancer

Year:

2019

File:

PDF, 1.03 MB

2019

57

Profile of lumacaftor/ivacaftor combination: potential in the treatment of cystic fibrosis

Pettit, Rebecca, Arends, Alexandria

Journal:

Orphan Drugs Research and Reviews

Year:

2015

Language:

english

File:

PDF, 476 KB

english, 2015

58

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer

Dockery, Lauren E., Rubenstein, Abby R., Ding, Kai, Mashburn, Sarah G., Burkett, Wesley C., Davis, Allison M., Doo, David W., Arend, Rebecca C., Moore, Kathleen N., Gunderson, Camille C.

Journal:

Gynecologic Oncology

Year:

2019

Language:

english

File:

PDF, 1.15 MB

english, 2019

59

2336 Novel PGF2a synthesis pathway in epithelial ovarian cancer

Hu, Muhan, Tiwary, Ekta, Arend, Rebecca, Miller, Michael

Journal:

Journal of Clinical and Translational Science

Year:

2018

Language:

english

File:

PDF, 50 KB

english, 2018

60

2336 Novel PGF2a synthesis pathway in epithelial ovarian cancer

Hu, Muhan, Tiwary, Ekta, Arend, Rebecca, Miller, Michael

Journal:

Journal of Clinical and Translational Science

Year:

2018

File:

PDF, 50 KB

2018

61

Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1

McCaw, Tyler R., Li, Mei, Starenki, Dmytro, Liu, Mingyong, Cooper, Sara J., Arend, Rebecca C., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D.

Journal:

Cancer Immunology, Immunotherapy

Year:

2019

Language:

english

File:

PDF, 7.56 MB

english, 2019

62

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

Arend, Rebecca C., Davis, Allison M., Chimiczewski, Przemyslaw, O'Malley, David M., Provencher, Diane, Vergote, Ignace, Ghamande, Sharad, Birrer, Michael J.

Journal:

Gynecologic Oncology

Year:

2019

Language:

english

File:

PDF, 870 KB

english, 2019

63

Biomarkers in ovarian cancer: To be or not to be

Arend, Rebecca, Martinez, Alba, Szul, Tomasz, Birrer, Michael J.

Journal:

Year:

2019

File:

PDF, 1.33 MB

2019

64

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

Arend, Rebecca C., Davis, Allison M., Chimiczewski, Przemyslaw, O'Malley, David M., Provencher, Diane, Vergote, Ignace, Ghamande, Sharad, Birrer, Michael J.

Journal:

Gynecologic Oncology

Year:

2019

File:

PDF, 870 KB

2019

65

Comparison of Minimally Invasive with Open Approach in Treatment of High Intermediate-Risk Endometrial Cancer

Kamal, Maahum, Roane, Brandon, Rushton, Tullia, Arend, Rebecca

Journal:

Journal of the American College of Surgeons

Year:

2019

File:

PDF, 82 KB

2019

66

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review

Arend, Rebecca, Westin, Shannon Neville, Coleman, Robert L.

Journal:

International Journal of Gynecological Cancer

Year:

2020

File:

PDF, 738 KB

2020

67

Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer

Betella, Ilaria, Turbitt, William J., Szul, Tomasz, Wu, Binghao, Martinez, Alba, Katre, Ashwini, Wall, Jaclyn A., Norian, Lyse, Birrer, Michael J., Arend, Rebecca

Journal:

Gynecologic Oncology

Year:

2020

Language:

english

File:

PDF, 866 KB

english, 2020

68

Antibodyâinduced vascular inflammation skews infiltrating macrophages to a novel remodeling phenotype in a model of transplant rejection

Wei, Xuedong, Valenzuela, Nicole M., Rossetti, Maura, Sosa, Rebecca A., NevarezâMejia, Jessica, Fishbein, Gregory A., Mulder, Arend, Dhar, Jayeeta, Keslar, Karen S., BaldwinIII, William M., Fairchil

Journal:

American Journal of Transplantation

Year:

2020

File:

PDF, 19.40 MB

2020

69

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

Arend, Rebecca C., Beer, Hannah M., Cohen, Yael C., Berlin, Suzanne, Birrer, Michael J., Campos, Susana M., Rachmilewitz Minei, Tamar, Harats, Dror, Wall, Jaclyn A., Foxall, McKenzie E., Penson, Richa

Journal:

Gynecologic Oncology

Year:

2020

File:

PDF, 491 KB

2020

70

The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer

Wall, Jaclyn A., Klempner, Samuel J., Arend, Rebecca C.

Journal:

Expert Opinion on Investigational Drugs

Year:

2020

File:

PDF, 716 KB

2020

71

The 2020 SGO Annual Meeting Report

Kim, Kenneth H., Moore, Kathleen N., Arend, Rebecca C., Bakkum-Gamez, Jamie N., Westin, Shannon N.

Journal:

Gynecologic Oncology

Year:

2020

File:

PDF, 238 KB

2020

72

Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer

Wall, Jaclyn A., Arend, Rebecca C.

Journal:

Annals of translational medicine

Year:

2020

File:

PDF, 134 KB

2020

73

Corrigendum to âWnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancerâ [Gynecologic Oncology 157 (2020) 765â774]

Betella, Ilaria, Turbitt, William J., Szul, Tomasz, BinghaoWu,, Martinez, Alba, Katre, Ashwini, Wall, Jaclyn A., Norian, Lyse, Birrer, Michael J., Arend, Rebecca

Journal:

Gynecologic Oncology

Year:

2020

File:

PDF, 316 KB

2020

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Z-Library Since 2009 support@z-lib.do

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски